Maxensia owor
ID: UNCST-2021-R014003
|
An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase: NeoSep1
REFNo: HS5639ES
In Part 2, a secondary objective is to provide a ranking of clinically relevant antibiotic regimens based on other efficacy and safety secondary outcomes, as well as on health economic measures and the potential selection of resistance. The trial data will provide data to inform the balance between efficacy, safety, costs (and cost-effectiveness and equity, using health economic analysis) and propensity for resistance selection (based on microbiology tests) that will influence facility-level and national decision-making about adoption of studied regimens, and potential future inclusion in WHO guidelines.,In Part 2, the primary objective is to provide a ranking of eight different clinically relevant antibiotic regimens for first-line empiric and second-line (after lack of response/deterioration) treatment in terms of 28-day mortality as the primary outcome measure. It will flexibly compare these multiple different relevant treatment regimens to enable the trial to be run in sites worldwide with very different background rates of different pathogens, of resistance and patterns of routine clinical care by randomising each participant to locally relevant antibiotic regimens agreed prior to site initiation. The trial will ensure generalisability by focusing inclusion based on clinical symptoms associated with high mortality risk in the NeoOBS study, which have been developed into a novel neonatal sepsis severity score – the NeoSep Severity Score.,
|
Uganda |
2025-04-02 9:04:16 |
2028-04-02 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Gloria Lubega
ID: UNCST-2025-R017180
|
A retrospective review of patients admitted with SARS-COV-2 at Entebbe regional referral hospital in Uganda across multiple waves.
REFNo: HS5695ES
I. To evaluate the mortality rate, risk factors associated with mortality and prolonged hospital admission among patients admitted with severe COVID-19 disease at ERRH.
II. To determine the time to discharge of patients admitted with severe COVID-19 disease at ERRH.
III. To describe the characteristics of patients across different age groups admitted with severe COVID-19 at Entebbe Regional Referral Hospital
IV. To describe treatment options offered to patients admitted with severe COVID-19 disease with reference to Uganda MoH and WHO recommended treatment options.
V. To compare characteristics of patients who were vaccinated against COVID-19 admitted with severe disease and unvaccinated patients admitted with severe COVID-19 disease.
|
Uganda |
2025-04-02 9:01:54 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Mark Kaddumukasa
ID: UNCST-2020-R001798
|
Building a Collaborative Research and Training Platform for HIV and Rheumatic and Musculoskeletal Diseases in Uganda
REFNo: HS5606ES
Objective 1. Establish the Ugandan Registry of RMDs in HIV (GEMINI), to create a foundation for future prospective studies on HIV and RMDs.
Objective 2. In a pilot study, among a subset of participants from GEMINI with both RA and HIV, compared to participants with HIV only and RA only, explore the impact of co-morbid disease status on markers of bone metabolism, bone mineral density, as well as quality of life and functional disability.
|
Uganda |
2025-04-02 9:00:14 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Sylvia Kusemererwa
ID: UNCST-2019-R001717
|
A phase III, multi-center, randomized, placebo-controlled, double-blind
study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises
REFNo: HS5607ES
To assess the efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without
hydroxyurea (HU)/hydroxycarbamide (HC) , on VOC rate in Sickle Cell Disease (SCD) patients aged 12 years and older who experience frequent vaso-occlusive crises (VOCs)
Primary Objective
1. To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, on the annualized rate of VOCs* that are HCP managed (including VOCs leading to management at a health care facility or those via remote consultation) over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in 12 months prior to the screening visit).
Secondary Objectives
1. To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without
hydroxyurea/hydroxycarbamide, on the annualized rate of all VOCs including VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) and VOCs that are self-managed without recommendations from HCP during the event over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in the 12 months prior to the screening visit).
2. To evaluate the annualized rate of VOCs by type of management between treatment arms over the planned 52-week treatment period:
VOCs that are HCP-managed at a health care facility
VOCs that are HCP-managed via remote consultation
Page 4 of 18
VOCs that are self-managed without recommendations from HCP during the event
VOCs that are HCP-managed via remote consultation or self-managed without recommendations from HCP during the event
|
Uganda |
2025-04-02 8:58:47 |
2028-04-02 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Aloysious Ssemaganda
ID: UNCST-2023-R008046
|
Clinical Performance of i.Mune CD4 diagnostic assay amongst people living with Human immunodeficiency virus (HIV) in Uganda (CPHL-CPSP_001)
REFNo: HS5680ES
The primary objective of this study is to evaluate the clinical performance and validity of the i.Mune CD4 diagnostic assay compared to WHO pre-qualified and CE-marked Abbott PIMA CD4 test using matched liquid and dried venous blood as well as capillary dried blood specimen
collected from people living with HIV in Uganda.
Secondary objectives of this study are:
-To validate the i.Mune CD4 diagnostic assay using the Applied Biosystems™ QuantStudio 5 PCR System in Uganda to support WHO pre-qualification.
-To establish trueness of measurement of the i.Mune CD4 diagnostic assay using the LightCycler 480 Instrument II and the LightCycler PRO in comparison to the reference method (Abbott CD4 PIMA) to support CE-marking of the assay.
|
Uganda |
2025-04-02 8:53:21 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
CAROLYNE OLEO
ID: UNCST-2024-R003845
|
CHARACTERIZATION OF CLINICAL OUTCOMES AMONG AMBULATORY GYNECOLOGY SURGERY RECIPIENTS AT KYABIRWA SURGICAL CENTER, BUDONDO SUB COUNTY, JINJA CITY
REFNo: HS5656ES
3. To disaggregate the clinical outcomes of among ambulatory gynecological surgery recipients at Kyabirwa surgical center, with their characteristics ,2. To develop a typology of the clinical outcomes among ambulatory gynecological surgery recipients at Kyabirwa surgical center, Budondo sub county, Jinja city,1. To classify the clinical outcomes among ambulatory gynecological surgery recipients at Kyabirwa surgical center, Budondo sub county, Jinja city,To characterize the clinical outcomes among ambulatory gynecological surgery recipients at kyabirwa surgical center, Budondo sub county, Jinja city,
|
Uganda |
2025-04-02 8:52:03 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Adoke Yeka
ID: UNCST-2021-R004300
|
Assessing durability of PermaNet Dual and PermaNet 3.0 under field conditions in Northern Uganda.
REFNo: HS5657ES
1. To compare the attrition and physical integrity of PermaNet Dual nets to PermaNet 3.0 nets in multiple locations across Northern Uganda over a three-year period, and to estimate median LLIN survival.
2. To characterize the chemical and entomological attributes of PermaNet 3.0 and PermaNet Dual nets over a period of three years after the mass distribution campaign.
3. To provide insight into the community acceptance of PermaNet Dual relative to PermaNet 3.0, and describe social and behavioural aspects related to net use and net care.
4. To assess the impact of net use and net care practices on the functional survival and insecticidal activity of the LLINs across the districts and across time.
|
Uganda |
2025-04-02 8:50:02 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Stephen Asiimwe
ID: UNCST-2019-R000059
|
Uganda Lung Health Study
REFNo: HS5678ES
To identify individuals at highest risk for COPD early in the disease course and intervention targets for preventing disease progression among young adults.
|
Uganda |
2025-04-02 8:46:08 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Henry Mugerwa
ID: UNCST-2019-R000420
|
A phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises
REFNo: HS5274ES
Primary Objective: To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, on the annualized rate of VOCs* that are HCPmanaged (including VOCs leading to
management at a health care facility or those managed via remote consultation) over the planned 52-week treatment period in SCD
patients aged 12 years and older with a history of frequent VOCs (4-12 events in 12 months prior to the screening visit).
Secondary Objective: Key secondary objective:
To compare the efficacy of 5 mg/kg of
crizanlizumab versus placebo, with or without
hydroxyurea/hydroxycarbamide, on the
annualized rate of all VOCs including VOCs that are HCP-managed (including VOCs leading to
management at a health care facility or those managed via remote consultation) and VOCs that are self-managed without recommendations from HCP during the event over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in the 12 months prior to the screening visit).
To evaluate the annualized rate of VOCs by type of management between treatment arms over the planned 52-week treatment period:
VOCs that are HCP-managed at a health
care facility
• VOCs that are HCP-managed via remote
consultation
• VOCs that are self-managed without
recommendations from HCP during the
event
• VOCs that are HCP-managed via remote
consultation or self-managed without
recommendations from HCP during the
event
• To evaluate the time to first VOC that is HCPmanaged (including VOCs leading to
management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the proportion of participants free from VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the duration of VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the safety and immunogenicity of crizanlizumab 5 mg/kg over the 2-year study
period.
To explore the efficacy of crizanlizumab 5 mg/kg over the 2-year study period.
To explore the proportion of VOCs that are selfmanaged without recommendations from HCP during the event, versus VOCs that are HCP-managed (including VOCs leading to
management at a health care facility or those managed via remote consultation) between treatment arms over the planned treatment period of 52 weeks.
To explore the proportion of VOCs that are HCP-managed via remote consultation versus VOCs that are HCP-managed at a healthcare facility between treatment arms over the planned 52-week treatment period.
To explore the incidence rates of all VOCs,
VOCs that are HCP-managed at a healthcare
facility, VOCs that are HCP-managed via remote consultation, VOCs that are HCP-managed,VOCs that are self-managed without
recommendations from HCP during the event,
VOCs that are HCP-managed via remote
consultation or self-managed without
recommendations from HCP during the event, by treatment arm.
To explore quality of life in each treatment arm (ASCQ-Me Short Forms: emotional impact, sleep impact, and joint stiffness).
To explore healthcare facility resource utilization (inpatient hospital admission, emergency room visit, urgent care/clinic visit, infusion center visit)between treatment arms over
the planned 52-week treatment period.
To explore the pharmacokinetics (PK) profile of crizanlizumab at 5 mg/kg.
To explore the pharmacodynamics (PD) (Pselectin inhibition) of crizanlizumab at 5 mg/kg.
To explore biomarkers [p-selectin (free and
total)] and CRP].
To explore exposure-response relationship.
|
Uganda |
2025-04-02 8:43:56 |
2028-04-02 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Taremwa Danison Danison
ID: UNCST-2024-R002981
|
AN OPTIMIZED ENSEMBLE DEEP LEARNING MODEL FOR MAIZE YIELD PREDICTION
REFNo: SIR375ES
General Objective of the Study
The general objective of the study will be to develop an optimized ensemble deep learning model to improve the accuracy of maize yield prediction, thereby enhancing decision-making by stakeholders in the agriculture sector.
Specific Objectives of the Study
i. To investigate the challenges of the current yield forecasting models and remote sensing technologies that will be used to generate variables for predicting maize yields using remote sensing data.
ii. To design and develop an optimized CNN-LSTM model using Bayesian approaches for the prediction of maize yields in Uganda.
iii. To evaluate the performance of the developed model for maize yield estimation.
|
Uganda |
2025-04-02 8:32:18 |
2028-04-02 |
Engineering and Technology |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|